EPZMinactive
Epizyme, Inc.
Biopharma developer (SEC filing verified)·Commercial·CEO: Grant Bogle
OncologyNephrology
Run Epizyme, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Epizyme, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Regulatory
Frequently asked questions
Who is the CEO of Epizyme, Inc.?
Grant Bogle is the chief executive officer of Epizyme, Inc. (EPZM).
What therapeutic areas does Epizyme, Inc. focus on?
Epizyme, Inc. develops therapies across Oncology, Nephrology.
923 active companies304,861 SEC filings22,725 clinical trials
Citation log window (7 days): 13,363 recorded LLM calls; 0 block events, 0 warning events. These counts do not measure factual accuracy or research quality.Computed at
How we verify →The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.